Additional file 7

Table: Reported antibiotic use in the ten days prior to study enrolment in the study population

Characteristics	Total N	Antibiotic use reported n	%	p-value¥
Overall	19,700	7,258	36.8%	
Country				<0.001
CIV	5,529	659	11.9%	
BF	4,802	2,470	51.4%	
DRC	5,937	1,903	32.1%	
RSA	3,432	2,226	64.9%	
Syndrome				<0.001
AFDUC	7,203	2,198	30.5%	
GI	5,085	1,642	32.3%	
RTI	6,676	3,009	45.1%	
GI/RTI	736	409	55.6%	
Covid-19 pandemic				<0.001
Enrolled before	10,604	4,319	40.7%	
Enrolled during	9,096	2,939	32.3%	
Health facility				<0.001
Rural site	7,173	1,974	27.5%	
Urban site	12,527	5,284	42.2%	
Patient's residence (N=19,617)*				0.395
Village	8,624	3,142	36.4%	
City/Town	10,993	4,070	37.0%	
Age group (N=19,544)*				<0.001
<1 year	4,297	1,947	45.3%	
1-4 years	6,128	2,130	34.8%	
5-17 years	2,518	635	25.2%	
18-44 years	4,067	1,269	31.2%	
≥45 years	2,534	1,174	46.3%	
Sex (N=19,672)*				<0.001
Male	10,116	3,916	38.7%	
Female	9,556	3,327	34.8%	
Level of education (N=19,625)*				<0.001
No level of education	7,092	2,099	29.6%	
≤ 6 years	3,852	1,459	37.9%	
7-10 years	4,136	1,712	41.4%	
> 10 years	4,545	1,945	42.8%	
Employment (N=19,331)*				<0.001
Not working	8,819	3,497	39.7%	
Self-employed	6,912	2,140	31.0%	
Part time employed	966	391	40.5%	
Full time employed	2,634	1,014	38.5%	
Weight categories (N=13,051)**				<0.001
Underweight	3,920	1,749	44.6%	
Normal	6,594	2,676	40.6%	
Overweight	1,606	569	35.4%	
Obese	931	331	35.6%	
Comorbidities (N=19,575)*				<0.001
No	18,378	6,612	36.0%	
Yes	1,197	569	47.5%	
Antimalarial use (N=19,265)*				<0.001
No	16,626	5,631	33.9%	
Yes	2,639	1,405	53.2%	

Other medication use (N=19,220)*				<0.001
No	12,155	3,391	27.9%	
Yes	7,065	3,601	51.0%	
Symptom onset (N=19,573)*				<0.001
0-3 days earlier	9,923	2,763	27.8%	
4-7 days earlier	7,391	3,276	44.3%	
8-10 days earlier	2,259	1,131	50.1%	

Legend: Enrolment from 1 February 2018 till 26 May 2022; AFDUC: acute febrile disease of unknown cause; GI: gastrointestinal infection; RTI: respiratory tract infection; *Variables with missing data <5%. **Missing data exceeds 5%. ¥ Pearson Chi-squared test used to determine p-value, although results should be interpreted with caution as the reference group of "no reported antibiotics" could include those who received antibiotics after the initial study enrollment period of 24-48 hours after presentation. IQR: Interquartile range